H&B Capital

H&B Capital (H&B Capital Advisors AB) was a Stockholm-based venture capital firm founded in 1999 that specialized in the healthcare and life sciences sectors across the Nordic region. The firm managed a private equity fund of approximately €95 million, targeting small to mid-sized growth companies in biotechnology, medical technology, health IT, and functional foods. Its notable portfolio included significant investments in companies such as Swedish Orphan Biovitrum (Sobi), Aerocrine, QuatRx Pharmaceuticals, and CellaVision. H&B Capital was backed by major institutional investors, including Skandia, the 6th Swedish National Pension Fund (AP6), and Orkla. The firm is currently inactive and listed as out of business.